NEW YORK (Reuters Health)—Apremilast improves clinical outcomes in patients with psoriatic arthritis and active psoriasis, according to results from the PALACE 3 randomized controlled trial. Apremilast, a phosphodiesterase 4 (PDE4) inhibitor, showed efficacy against psoriatic arthritis in the PALACE 1 trial. Dr. Christopher J. Edwards from University Hospital Southampton in the U.K. and colleagues evaluated…
Enthesitis: New Insights into the Pathogenesis, Diagnostic Modalities & Treatment
Enthesitis is a central feature of spondyloarthritis (SpA). This review article summarizes the substantial progress that has been made in addressing the pathophysiology, molecular mechanisms, genetic associations, clinical features, diagnostic modalities and treatment of enthesitis. Further examination into the role of the inflammatory mediators, including IL-17, IL-22, and IL-23 as well as potentially others, in driving enthesitis and bone formation will be important to direct our attention toward future therapeutic targeted pathways in patients with SpA…
Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk
NEW YORK (Reuters Health)—The newer disease-modifying drugs for rheumatoid arthritis appear to offer the same or even better cardiovascular (CV) protection than older tumor necrosis factor (TNF) inhibitors, hints a large study. “We really haven’t had a good understanding on where the non-TNF biologics and CV risk stand,” Dr. Jeffrey R. Curtis of the University…
Researchers Target Altered T Cell Metabolism in SLE to Reverse Lupus Immuno-Phenotype
A recent study on systemic lupus erythematosus examined the effects of metabolic modulators on the disease’s abnormal T cell metabolism. Using a combination therapy of metformin and 2-deoxy-D-glucose, researchers were able to normalize CD4+ T cell functions and restore defective IL-2 production in mice…
Listen to the Lungs: An Interview with Dr. Aryeh Fischer on ILD
In a recent interview, Aryeh Fischer, MD, addresses the importance of checking patients with autoimmune diseases for interstitial lung disease, noting that advances in technology and awareness can lead to early detection and affect patient outcomes…
VA Musculoskeletal Education Pilot Program Helps PCPs Treat Patients
To improve access to quality of care for patients with osteoarthritis and other musculoskeletal pain, the U.S. Department of Veterans Affairs (VA) launched a continuing education program designed to strengthen the musculoskeletal knowledge and skills of primary care providers (PCPs). In the program’s initial trial in 2012, 19 physicians were trained on exams, treatments and joint injections. Two years after course completion, some participants increased the number of intraarticular corticosteroid injections at their clinics without needing to refer patients to specialists…
3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA
Three clinical trials are evaluating subcutaneous sirukumab for safety and efficacy in treating rheumatoid arthritis. And a study found no significant difference in persistence and remission for TNF-α monotherapy when compared with TNF-α plus conventional DMARD combination therapy for treating psoriatic arthritis…
Large Group Study of Systemic JIA Patients Provides Insight into Disease Pathology
In a large group genetic analysis, researchers identified an association between the class II HLA region, including HLA-DRB1*11, and systemic juvenile idiopathic arthritis (sJIA), implicating adaptive immune molecules in sJIA’s pathogenesis and reinforcing its unique genetic position among JIA subtypes…
Small Increased Risk for CIN & Cervical CA with TNF Inhibitors
NEW YORK (Reuters Health)—Women with rheumatoid arthritis (RA) are at increased risk for cervical intraepithelial neoplasia (CIN), and those taking a tumor necrosis factor (TNF) inhibitor are at increased risk of cervical cancer, according to a study from Sweden. “Whether this (the increase in invasive cancers) was due to the TNF inhibitors, disease severity, or…
Opioid Investigated to Treat Acute & Chronic OA Pain; Plus New RA Treatment & More
In Phase 2 trials, the oral opioid, CR845, has proved promising in treating pain in patients with hip and knee osteoarthritis. Olokizumab is being investigated to treat RA, and in Canada, adalimumab has been approved to treat polyarticular JIA in 2–4 year-olds…
- « Previous Page
- 1
- …
- 231
- 232
- 233
- 234
- 235
- …
- 339
- Next Page »